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Abstract
Background: Idiopathic pulmonary fibrosis (IPF) is a severe and progressive respiratory disease with poor prognosis.
Despite the positive outcomes from recent clinical trials, there is still no cure for this disease. Pre-clinical animal
models are currently largely limited to small animals which have a number of shortcomings. We have previously
shown that fibrosis is induced in isolated sheep lung segments 14 days after bleomycin treatment. This study
aimed to determine whether bleomycin-induced fibrosis and associated functional changes persisted over a
seven-week period.
Methods: Two separate lung segments in nine sheep received two challenges two weeks apart of either, 3U
bleomycin (BLM), or saline (control). Lung function in these segments was assessed by a wedged-bronchoscope
procedure after bleomycin treatment. Lung tissue, and an ex vivo CT analysis were used to assess for the
persistence of inflammation, fibrosis and collagen content in this model.
Results: Fibrotic changes persisted up to seven weeks in bleomycin-treated isolated lung segments (Pathology
scores: bleomycin12.27 ± 0.07 vs. saline 4.90 ± 1.18, n = 9, p = 0.0003). Localization of bleomycin-induced injury and
increased tissue density was confirmed by CT analysis (mean densitometric CT value: bleomycin −698 ± 2.95
Hounsfield units vs. saline −898 ± 2.5 Hounsfield units, p = 0.02). Masson’s trichrome staining revealed increased
connective tissue in bleomycin segments, compared to controls (% blue staining/total field area: 8.5 ± 0.8 vs.
2.1 ± 0.2 %, n = 9, p < 0.0001). bleomycin-treated segments were significantly less compliant from baseline at 7 weeks
post treatment compared to control-treated segments (2.05 ± 0.88 vs. 4.97 ± 0.79 mL/cmH20, n = 9, p = 0.002). There
was also a direct negative correlation between pathology scores and segmental compliance.
Conclusions: We show that there is a correlation between fibrosis and correspondingly poor lung function which
persist for up to seven weeks after bleomycin treatment in this large animal model of pulmonary fibrosis.
Background
Idiopathic pulmonary fibrosis is a progressive and fatal
disease due to the resulting functional impairment and re-
spiratory failure caused by aberrant extracellular matrix
remodelling in the lung parenchyma [1]. Whilst there are
now two therapies available to slow the progression of the
disease [2, 3], these therapies are unlikely to be effective in
the entire spectrum of IPF patients and still do not
address the fibrosis that results from aberrant wound heal-
ing and is a key contributor to organ failure.
The bleomycin model has become the most widely
used and characterised animal model of pulmonary
fibrosis to investigate IPF and typically involves an intra-
tracheal administration of a single dose of bleomycin to
induce fibrosis in the lung parenchyma [4]. Whilst bleo-
mycin is considered the most effective method to induce
reproducible and consistent experimental fibrosis, there
is still concern regarding the temporal aspects and trans-
lation ability of this model [4]. The bleomycin model has
two distinct phases: the inflammatory stage occurring
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within the first two weeks post injury which then sub-
sides to the fibrotic phase [5, 6], which appears to have
an active period followed by a late fibrosis phase [7].
The longevity of fibrosis in the rodent models is not
well defined, with different durations reported between
various studies. Resolution of fibrosis is one of the most
commonly stated limitations of bleomycin models; based
on reports showing that fibrosis is short-lived and usu-
ally resolves within six weeks post-injury [8, 9]. However,
there are several studies that challenge this concept, with
evidence that fibrosis is maintained over a longer period
of time following either a single dose or multiple doses
of bleomycin [7, 10–12]. For appropriate testing of anti-
fibrotics therapies, intervention should ideally occur
within the fibrotic phase of the injury response. Import-
antly, the fibrotic phase in the animal model utilised for
the trial should be sustained for a lengthy period to de-
termine the true drug efficacy, without being con-
founded by a natural resolution of the induced fibrosis.
The uncertainty about the duration and persistence of fi-
brosis in some bleomcyin rodent models has led some
researchers to cast doubt over the appropriateness of
using this model to trial novel therapies, one of the pri-
mary uses of the model [9]. For this reason, it is critical
to therefore determine whether a measurable fibrotic re-
sponse is maintained for a sufficient period of time to
trial novel therapies during the fibrotic phase in any ani-
mal model being considered for such experiments.
We have previously characterized a sheep model of
pulmonary fibrosis using a two hit segmental infu-
sion of bleomycin approach [13]. This model enables
fibrosis to be produced within isolated lung seg-
ments, thus providing internal controls and the abil-
ity to control the severity of the fibrotic response
induced without the risk of mortality or compromis-
ing the animals’ overall respiratory health, a common
problem associated with traditional bleomycin models
[11, 12]. Importantly, the method used in this model
allows for reliable lung function data, such as lung
compliance, to be sequentially collected in the same
animals throughout the study. As the previous study
examined the acute early phase of fibrosis, up to
2 weeks post-bleomycin, the purpose of the current
study was to characterize later stages of segmental
pulmonary fibrosis in the sheep model. We sought to
determine what structural and functional changes
persisted 7 weeks beyond the acute injury stage [13].
This time-frame was chosen based on the premise that if
bleomycin-induced fibrosis was resolving in the sheep
model, the improvement in lung pathology would be able
to be identified at 6 weeks as reported for fibrosis reso-
lution in some murine models. The overall goal of the
study was to determine whether lung function deterio-
rated and fibrosis persisted in this model such that in
future studies the model may be useful for testing clinic-




Nine female merino sheep aged between 9 months and
1 year were utilised in the study. Animals were housed
indoors and received anthelminthic to treat for any
existing parasitic disease. The sheep were judged to be
free from significant pulmonary disease on the basis of
clinical examination before the commencement of ex-
periments and on inspection of gross pathology at aut-
opsy. The Animal Experimentation Ethics Committee of
the University of Melbourne, which adheres to the Aus-
tralian Code of Practice for the care and use of labora-
tory animals for scientific purposes, approved all
experimental procedures outlined below.
Bleomycin administration and treatment protocols
Fibrosis was induced within specified regions of the lung
of all treated animals, as indicated in Fig. 1a, using
pharmaceutical grade bleomycin sulphate (Hospira,
Melbourne, Australia). Bleomycin sulphate was made up
at a concentration of 0.6 U bleomycin/mL saline as previ-
ously described [13]. Bleomycin solution was administered
via the biopsy port of a fibre-optic bronchoscope to the
appropriate lung segments as a 5 ml bolus (total dose of
3U/segment Fig. 1a). The bleomycin and saline control
treatments were randomised between the most caudal
segments of the left and right caudal lobes in different
sheep. In particular, for sheep 1–4, bleomycin was infused
into the left caudal lobes, while the right caudal lobes
acted as internal controls and were with infused with
5 mL of sterile saline solution. These treatments were
reversed between the lobes for sheep 5–9. Bleomycin
and saline were first administered at week −2 and re-
peated two weeks later at week 0. (Fig. 1b). Sheep
were then euthanized by an intravenous overdose of
barbiturate (Lethabarb, Veterinary Clinic, Werribee,
Australia) at week 7 as outlined in Fig. 1b; for tissue
collection and analysis
Necropsy and tissue sampling
Following euthanasia, the lungs were removed and targeted
lung segments identified and carefully dissected free from
surrounding tissue. Individual segments were then inflated
with a 1:1 mixture of OCT and sterile PBS solution. This
inflation procedure maintains lung segment tissues in an
inflated state prior to either fixation in formalin, or freezing
for cryo-sectioning. This allows unfixed tissues to undergo
other processing procedures, as is standard procedure in
our laboratory [13–15]. Several 2 mm thick transverse slices
were taken and processed as follows: an area of lung slice
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derived from the most caudal region of each treated
segment was fixed in 10 % neutral-buffered formalin
and processed in paraffin for histopathology assess-
ment. Remaining lung slices were embedded in OCT
and frozen in cryo-moulds on aluminium boats float-
ing on liquid nitrogen. These were kept at −80 °C for
cryo-sectioning and immmunohistology.
Analysis of segmental lung function
Segmental compliance (Cseg) was assessed using pressure
responses to flow in the different segments as indicated
Fig. 1a and b in awake, consciously breathing sheep using
a wedged-bronchoscope technique as previously described
[13] Briefly, a custom-built Segmental Lung Airway Moni-
toring (SLAM) System was used to monitor the segmental
flow and pressure. After first determining the broncho-
scope resistance to the set flow, the bronchoscope was
wedged into an airway in the lung segment of interest and
a constant flow (6 mL/s) of 5 % CO2 in AIR was passed
through the working channel of the bronchoscope.
Segmental lung compliance was calculated as previously
described [13]. Briefly, after the bronchoscope was wedged
into the specific region of the lung, pressure was allowed
to reach a steady state. After approximately 5 s at steady
state, airflow was interrupted turning off the airflow sup-
ply. Segmental compliance is then calculated from the
pressure-flow decay curve generated from this procedure,
as previously described [13, 16, 17]. The process was re-
peated 3 times for each segment and expressed as an
average value for Cseg The pressure was recorded by a
PM-1000 Transducer Amplifiers (CWE Inc., Admore,
USA) and flow was recorded using a mass flow meter
(824-S, SIERRA INSTRUMENTS, Monterey, USA). Data
was acquired with Data Acquisition Card (PCI-6233;
National Instruments Corp., Austin, USA) and was ana-
lysed with the SLAM system (Latitude E6520, Dell Com-
puter Corporation, Texas USA and LabVIEW, National
Instruments Corp., Austin, USA). All resistance measure-
ments were corrected for the resistance of flow through
the working channel of the bronchoscope.
Histology
Paraffin-embedded tissue sections (5 μm) were stained
with haematoxylin and eosin Y (H&E) for general hist-
ology and the assessment of pathological changes and
Masson’s trichrome staining was used to identify
changes to collagen content within the lung parenchyma
as previously described [18]. Fibrotic lung injury was
assessed morphologically by semi-quantitative and quan-
titative parameters as follows:
Semi-quantitative Morphological Index (SMI)
Histopathology of lung parenchyma was assessed by an
experienced pathologist (BB) blinded to the treatment
groups using a semi-quantitative scoring system, as pre-
viously described [13]. Briefly, the criteria used gives
score indices separately for both inflammation and
fibrosis pathology, and these score indices added to-
gether give an ‘overall pathology score’.
Quantitative Image Analysis (QIA)
a) Fibrosis fraction: The degree of fibrosis, or collagen
content, was quantified to give an indication of
changes for overall collagen content within the
parenchymal tissue using a previously described
method [6]. Briefly, Masson’s trichrome stained
slides were scanned into a digital format using Mirax
Fig. 1 Challenge and sampling regime. Schematic diagram depicting the bleomycin and saline treatments administered to individual lung
segments (a) two spatially distinct lung segments, which received the different treatments. The left caudal (LC) segment in sheep 1–4 received
3U bleomycin per segment, and the right medial (RC) segment received sterile saline as a control. The treatment and control segments were
reversed in sheep 5–9 (b) Diagram indicating the time line for treatment administration, lung function and sample collection
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slide scanner (Carl Zeiss Micro-Imaging, Jena,
Germany). Ten consecutive, non-overlapping fields
were selected for analysis, which lacked obvious
airways and/or blood vessels. Each field was analysed
using Image Pro plus (Version 6.3 for Windows,
Media Cybernetics, Bethseda, Maryland, USA), using
the ‘Colour selector’ tool to measure the area blue
stained tissue (collagen) within the each field. The
fraction of blue stained collagen areas for each of
the ten fields was averaged for each slide. The area
of the fraction of fibrosis is expressed as a percentage
of the total field area.
b) Morphometrics: Paraffin-embedded sections of lung
tissue were stained with H&E for morphometric
assessment. Digital images of lung parenchyma from
control- and bleomycin-treated lung segments were
imported into Image Pro Plus software for analysis.
Measurements were made by superimposing
custom-designed test grids over the lung parenchyma,
which were generated using Image Pro. Tissue and
airspace fractions were determined within parenchymal
tissue by point-counting methods, as previously
described [19, 20]. Analyses were performed from a
total of 15 fields at a final magnification of x200.
Ex-vivo CT analysis
CT analysis was performed on one set of lungs ex-vivo
to localise the fibrosis and density changes in the lung.
Selection was based on lung function results, with the
sheep showing the most prominent loss in lung compli-
ance chosen for the analysis. Following euthanasia, the
lungs were carefully dissected out without damaging the
parietal pleura and placed immediately on ice. The tra-
chea was secured in an upright position to prevent any
fluids filling the lungs.
CT scans were acquired using a 16 slice multirow de-
tector CT scanner (Siemens Emotion 16, Siemens
Erlangen, Germany). The lungs were placed in a water
bath to allow for full inflation of the lungs and prevent
artificial atelectasis from the pressure of the table. A 3 L
syringe was tightly secured in the tracheal lumen and
used to inflate the lungs throughout the scan. The scan-
ner configuration was 16x0.6 mm; giving an effective
slice of 0.75 mm, with a complete scan time of 97.75 s,
at a pitch of 0.4, and rotation time of 1 s. The reference
mAS was 70 and effective mAS 65. Two reconstructions
of the acquired dataset were made: lung window with
edge enhancement filter, soft tissue window with
smoothing filter.
To analyse the tissue density, the reconstructed images
were viewed using OsiriX Imaging software (Pixmeo,
Switzerland, (19), which converted voxels to Hounsfield
Units (HU) selecting air as −1000 and water as 0. The
reconstructed image was loaded in the segmentation
editor and the box selector tool was utilized to select the
region of interest for saline and bleomycin-treated areas
of lung. For the CT analysis, measurement of the tissue
density was performed on 10 representative slices of the
targeted regions to give a mean tissue density for each
differentially treated lung segment.
Collagen concentration
The hydroxyproline assay was used to extrapolate the col-
lagen content and concentration of each segment, as de-
scribed previously [21, 22]. Briefly, frozen lung tissues
from each segment were lyophilized to dry weight, hydro-
lyzed in 6 M HCl, and assessed for hydroxyproline content
by measuring the absorbance of reconstituted samples (in
0.1 M HCl) at 558 nm using a Beckman DU-64 spectro-
photometer (Beckman Coulter Inc, Brea, CA). Hydroxy-
proline content was determined from a standard curve of
trans-L-hydroxy-L-proline (Sigma-Aldrich). Collagen con-
tent was extrapolated by multiplying the hydroxyproline
measurements by 6.94 (based on hydroxyproline repre-
senting ~14.4 % of the amino acid composition of collagen
[23] in most tissues) and then expressed as a proportion
of the dry weight tissue to yield collagen concentration
(which was expressed as a percentage).
Immunohistochemistry
Immunohistochemistry was performed on frozen tissue
sections as previously described [14, 15]. Sections were
fixed with 100 % cold ethanol for 10 min and were sim-
ultaneously blocked for endogenous peroxidase with 3 %
H2O2 (Univar, Knoxville, Vic, Australia). Sections were
then pre-blocked using blocking solution for 30 min
(1 % bovine serum albumin, 5 % normal sheep serum in
PBS). After blocking, sections were incubated with the
primary antibodies (See Table 1). After washing, sections
were incubated for with appropriate secondary anti-
bodies (See Table 1) for 1 h. Sections were then washed
and a peroxidase-based detection system was used for
visualization. Specificity was determined by omission of
the primary antibody on secondary controls, and bio-
logically irrelevant isotype controls.
Lung parenchyma cell counts
Individual tissue sections immunohistochemically stained
with one of CD4, CD8 (see above) were assessed for the
number of positive cells in the parenchymal regions of the
lung. Regions of intact lung parenchyma were visualized
at 400x magnification using a microscope with graticule
attachment. All positive cells within the boundaries of the
graticule were counted and field of view was repositioned
to a new area as necessary to obtain a count of at least
100 positive cells, recording both the number of fields and
the total number of cells per sheep. The area of the
graticule at 400x magnification was determined to be
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0.078 mm2, this was used to calculate the cell density
(cells/area; data is presented as cells/mm2).
Collection of bronchoalveolar lavage
Bronchoalveolar (BAL) fluid was collected from all sheep
14 days prior to bleomycin administration from the re-
spective lung segments and then again at 2 weeks, 4 weeks
and 6 weeks (shown in Fig. 1b), as previously described
[18]. BAL samples were collected at a minimum of 3 days
either prior to, or after, lung function, with the final BAL
samples taken the week prior to final lung function test-
ing. The reason for the interval between lung function
testing and BAL sampling is that if these two procedures
are scheduled too close together, the first performed pro-
cedure influences parameters of the second performed
procedure, leading to spurious data. To collect BAL cells/
fluid, a flexible fibre-optic bronchoscope was advanced
into the selected lung segments and a lavage was collected
by instillation and withdrawal of approximately 10 mL
aliquots of PBS solution. The samples were placed immedi-
ately on ice. The cells were separated from the supernatant
by centrifuging the lavage fluid for 7 min at 1000 rpm to
remove cells. Supernatant was stored at −80 °C until use in
ELISA.
TGF-β1 ELISA
Total TGF-β1 was assessed in BAL fluid by ELISA
using commercially available kit, according to kit in-
structions (Quantikine; R&D Systems, Minneapolis,
MN). Neat BAL samples were prepared for the assay
following protocol for low protein samples, as indi-
cated by the kit instruction. Results were normalized
for protein concentration using a TGF- β1 standard
and control (included in the kit).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
for Windows Version 6.0 (GraphPad Software Inc, La
Jolla, USA. Each parameter was assessed for Gaussian
distribution both visually and using the D’Agostino &
Pearson omnibus normality test. Comparisons between
individual lobes within the same sheep and comparisons
of pre- and post- treatment were performed using paired
analyses. For normally distributed data, paired two-tailed
t test were used. Wilcoxon matched-pairs signed rank
test was used for data that did not meet assumptions re-
quired for parametric testing. To assess for associations
between two measured parameters, Correlations were
assessed by the Spearman correlation coefficient (rs) A P
value of <0.05 was taken as significant. Values are re-
ported as mean ± SEM, unless stated.
Results
Isolation of fibrosis to bleomycin-treated lung region
To confirm that the fibrosis induced by the segmental ad-
ministration of bleomycin was localized to the specifically
treated lobes, an ex-vivo CT scan was performed on lungs
removed at autopsy (Fig. 2). This scan confirmed that the
bleomycin injury was confined to a small region of the
lobe following administration using the bronchoscope,
while the remainder of the lung has a normal radiological
appearance (Fig. 2c-e). Measurements of the tissue
density showed that the bleomycin-treated segment
had significantly increased mean Hounsfield units
compared with saline treated regions, which exhibited
tissue density of a healthy lung (mean densitometry
CT value: bleomycin −698 ± 2.95 Hounsfield units vs.
saline −898 ± 2.5 Hounsfield units, p = 0.02, n = 1)
Decreased lung compliance persists in bleomycin-treated
segments
Temporal changes in lung function in the individually
treated segments were assessed in all sheep by meas-
uring lung function before bleomycin or saline treat-
ment, and again at 2, 4 and 7 weeks post –treatment.
Our results showed that there was a significant de-
crease in the percentage change in compliance from
baseline values observed at 2 weeks in segments
treated with bleomycin compared to saline control
segments (−75.9 ± 4.6 vs 26.5± 28.7 %, p=0.002, n=9,
Fig. 3b). Lower lung compliance values persisted in
the bleomycin treated segments throughout the
remainder of the time-points assessed, as indicated by
the significant difference between the bleomycin and
saline-treated segments at both 4 and 7 weeks post
bleomycin-treatment (4 weeks: −61.9 ± 10.73 vs 37.7
±46.1 %, p=0.009, n=9, Fig. 3c and 7 weeks: − 42.5 ± 18.5
vs 75.2 54.8 %, p=0.002, n=9, Fig. 3d).
Fibrotic remodelling changes present in bleomycin-
treated segments up 7 weeks post-injury
Histological examination was performed on both saline
treated and bleomycin-treated lobes taken at autopsy
and was quantified using a scoring system outlined in
Table 1 Summary of antibodies used for immunohistochemistry
Primary Antibody Supplier Dilution Incubation Secondary Antibody
Mouse anti-αSMA Sigma-Aldrich, 1:800 2 hrs Rabbit anti-mouse Ig/HRP
Mouse anti-CD4 AbD Serotech, Raleigh, USA neat 2 hrs Rabbit anti-mouse Ig/HRP
Mouse anti-CD8 AbD Serotech, Raleigh, USA neat 2 hrs Rabbit anti-mouse Ig/HRP
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methods. The saline-treated segments all had normal
architecture (Fig. 4a), with no prominent inflammation
or fibrosis in the alveoli space or walls. There were no
major pathological findings within the lung parenchyma,
in line with typical healthy lung tissue (Fig. 4c, d, e).
In bleomycin-treated lobes, extensive structural changes
were observed in the lungs 7 weeks after the final bleo-
mycin administration (Fig. 4b). Fibrosis was present in
both alveolar wall and space, which had a multifocal ap-
pearance (Fig. 4b). Quantification of the injury showed
that the overall injury score and fibrosis scores were sig-
nificantly higher than that of saline treated controls (Over-
all Pathology scores: 12.27 ± 0.07 vs. 4.90 ± 1.18, p=
0.0003, n=9 Fig. 4c and Fibrosis scores: 7.2 ± 0.7 vs 2.0 ±
0.8, p=0.004, n=9, Fig. 4d). There was still some cellular
infiltrate observed within the damaged regions of the lung,
Fig. 2 CT-analysis reveals isolation of fibrosis to specifically treated lung region. CT analysis was performed on one set of lungs ex-vivo to localise
the fibrosis and density changes in the lung (a) Siemens Emotion 16 was used (configuration 16x0.6 mm, effective slice. Two reconstructions of
the acquired dataset were made: Lung window with edge enhancement filter, Soft tissue window with smoothing filter. (b) Set-up of ex-vivo
lung scans: Lungs were floated in a water bath and trachea was secured to a 3 L syringe to inflate the lungs throughout scan. Representative
images obtained from CT scan highlighting the isolation of fibrosis to the bleomycin-treated (left caudal) lobe. Images show (c) Volume reformats
(Blue 3D) model of the lungs. Areas of air show as hollow surrounded by the blue. Areas of increased density show up as the yellow colour. (d)
Slice-image from reconstructed “Lung Thin” dataset, (e) Slice image from reconstructed sagittal reformats
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with inflammation scores were significantly elevated in
comparison to saline treated lobes (1.3 ± 0.1 vs. 0.7 ± 0.1,
p=0.0002, n=9, Fig. 4e). However, a comparison of the
scores from the current study, at 7 weeks post-bleomycin
are compared to our previous study [13], looking at injury
2 weeks post-bleomycin, indicates that the inflammatory
scores at 7 weeks were significantly lower than those
observed at the 2 week time-point (1.3 ± 0.1 vs. 7.7 ± 0.8,
p<0.0001, n=8-9, Fig. 5c). There was a significant differ-
ence in the overall score between the two time points,
which included the inflammatory score component
(2 weeks vs. 7 weeks: 17.8 ± 1.5 vs 12.3 ± 0.9 p=0.009,
n=8-9, Fig. 5a). Importantly, despite the reduced inflam-
mation in the tissue at the seven-week post-injury time-



























C s e g 2 w e e k s



























C s e g : 4 w e e k s



























C s e g : 7 w e e k s





C s e g B a s e lin e


















A B C D
Fig. 3 Decreased lung compliance persists in bleomycin-treated segments. Graphs show changes to segmental compliance values over time in
the different lung segments (Cseg), as percentage change from pre-treatment values. a baseline compliance values, b Cseg at 2 weeks, c Cseg at
4 weeks and d Cseg at 7 weeks. Significance was determined using a matched-pairs t-test (Wilcoxin for non-normal data), ** p <0.01
Fig. 4 Fibrotic remodelling changes present in bleomycin-treated segments up 7 weeks post-injury. Panels depict histology of H&E stained
sections of lungs segments taken at autopsy. a saline-treated segment. b bleomycin-treated segment, patchy areas of inflammation and fibrosis.
Semi-quantitative scoring, shown is graphs (c-e) of the pathology revealed increased fibrosis and inflammation in bleomycin-treated segments at
7 weeks post-treatment, compared to saline treated controls (Graphs c-e.). Significance was determined using paired T-test (Wilcoxin for
non-normal data) between treatment groups and unpaired T-tests between time points,***p<0.001
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point compared to the two-week time-point, there was no
difference in fibrosis scores between these two time-
points (2 weeks vs 7 weeks: 9.1 ± 0.7 vs 7.2 ± 0.7, p=0.08,
n=8-9 Fig. 5b).
Immunohistochemistry for CD4 and CD8 inflamma-
tory cells revealed there was no significance difference in
the number of either of these cell types between the sa-
line control and bleomycin treated segments at seven
weeks after bleomycin injury (CD4: 12.1 ± 3.3 vs. 14.9 ±
1.9 cells/mm2, p=0.4, n=9, Fig. 6a; and CD8: 15.4 ± 4.4
vs. 14.7 ± 4.3 cells/mm2, p=0.9, n=9, Fig. 6b).
The percentages of tissue space and airspace were
measured in the segments. Compared to the saline-
treated controls, the mean percentage of tissue space
was significantly higher in the bleomycin-treated seg-
ments (21.7 ±1.04 vs. 42.4 ± 1.8 %, p<0.0001, n=9,
Fig. 7a). Correspondingly, the airspace percentage was
significantly reduced in the bleomycin-treated segments,
compared to saline-treated control segments (57.6 ±1.8
vs. 78.3 ±1.0 %, p<0.0001, n=9, Fig. 7b).
Elevated collagen and connective tissue levels seven
weeks post- injury
Masson’s trichrome staining and hydroxyproline assess-
ments were used to determine the presence of connect-
ive tissue and collagen changes in the lungs seven weeks
post bleomycin injury. An assessment of Masson’s trich-
ome staining revealed the presence of extensive connect-
ive tissue in the remodelled regions of the bleomycin-
treated lobes (Fig. 8b), compared to the minimal staining
observed in saline-treated control (Fig. 8a), confirmed by
quantification of the positive staining area in parenchy-
mal tissue (8.5 ± 0.8 vs 2.1 ± 0.2 %, p<0.0001, n=9,
Fig. 8c). The hydroxproline assay showed a measurable
increase in lung collagen concentration levels in most
bleomycin-treated lobes compared to their saline treated
counterparts, but this did not reach statistical significance
given the variation in data (7.5 ± 1.1 vs 4.4 ±0.5 %, p=0.06,
n=9, Fig. 8d).
Histopathology correlates to lung function changes
The histopathology score (SMI) was compared to
changes in lung compliance in the bleomycin-treated
segments. The overall pathology score showed a strong
inverse correlation to both the compliance values mea-
sured at 7 weeks post-bleomycin (rs= −0.79, p=0.01, n=9
Fig. 9), in the corresponding segments and also in the
percentage change of compliance from pre-treatment
values at 7 weeks post-bleomycin (rs= −0.71, p=0.03,
n=9) This correlation shows the close link between com-
pliance and the pathology scores in this model.
Pro-fibrotic environment prevails in bleomycin-treated
lobes
Myofibroblasts are considered to be a key cell type in
driving the persistent and progressive fibrosis in IPF.
The presence of contractile myofibroblasts was observed
in damaged regions of the interstitial and alveolar space,
based on intense positive staining for alpha smooth
muscle actin (α-SMA) (Fig. 10b, arrowheads). Thin,
spindle like projections of the positive α-SMA stain
could also be observed in the remodelled alveolar re-
gions. The staining pattern observed in the saline-
treated control was as expected, with positive staining
localising predominantly to around the interstitial space
of the alveolar duct (Fig. 10a, arrowheads).
The levels of the TGF-β protein were also measured in
BAL samples taken at several key time-points from the
bleomycin-treated lobes as an indicator of the level of fi-
brotic activity in the bleomycin-treated lobes (Fig. 11).
As expected, TGF- β levels were significantly elevated
from pre-treatment values at 2 weeks post injury (158 ±
62.7 vs. 672 ± 121 pg/mL, p=0.001, n=9, Fig. 11). At
6 weeks post-bleomycin, the response was much more
Fig. 5 Reduction in inflammation over time. A comparison of injury scores at 7 weeks in this study to lung tissue taken 2 weeks post-injury from
our previous study [13] showed that overall pathology was higher at 2 weeks than 7 weeks (Graph a), but the degree of fibrosis was similar
between the two time-points (Graph b), whist the degree of inflammation was decreased at 7 weeks post-injury from inflammation observed at
2 weeks (Graph c). Significance was determined using unpaired T-tests between time points and is denoted, **p<0.01, ****p<0.0001
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varied: several sheep showed a further elevation in the
levels detected at 2 weeks, some showed similar levels
and other sheep showed a decrease back to baseline
levels Fig. 11. Overall, the levels for all the bleomycin-
treated segments at 6 weeks compared to baseline was in-
creased, although this did not reach statistical (663 ± 226
vs. 158 ± 62.7 μg/mL, p=0.12, n=9, Fig. 11).
Discussion
Despite recent advances in therapeutics available for IPF,
there is a continued need to find more effective therap-
ies to directly prevent or ideally reverse the fibrosis in
the lungs. The development of novel therapies relies on
how well experimental animal models are able to trans-
late findings to clinically related outcomes but there is
still much debate around the reliability of current
animal models for pulmonary fibrosis. While functional
assessments are key end-points in clinical trials and dis-
ease staging in IPF [24], only a few small animal models
of pulmonary fibrosis incorporate long term lung func-
tional measurements into their protocols. Here, we
present a model that offers the ability to measure not
only histological and biochemical changes in the lung,
but also incorporates long-term lung function monitor-
ing throughout the experiment. The segmental infusion
approach used in the current model offers several key
advantages over conventional small animal models,
which typically induce fibrosis to the whole lung.
Firstly, the model has the ability to temporally deliver
infusions of bleomycin to discrete lung segments. This
not only reduces the number of animals used for an ex-





































































Fig. 6 T cell subpopulations in the parenchyma in the different lobes at 7 weeks post injury were assessed on histological sections with
antibodies raised against the respective antigens using a horseradish peroxidase based detection system. Counts expressed as cells per mm2 of
parenchyma . The number of (a) CD4+ and (b) CD8+ Cytotoxic T cells helper cells in the bleomycin-treated lobes was not significantly different
from the saline–treated lobes
Fig. 7 Alveolar airspace is significantly reduced in response to bleomycin (b). Changes to alveolar tissue percentage, showing increased tissue
volume (a) and airspace percentage, showing decreased airspace volume (b), were assessed in H&E stained lung segments taken at autopsy.
Measurements were taken from three differentially treated segments in each sheep using point-counting methods. Fifteen fields were assessed in
each segment to obtain an average value. Values are shown as mean ±SEM for each segment for all animals, n=9. Significance was determined
using a matched- ANOVA ****, p<0.0001
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allowing for direct comparisons in the same animal be-
tween an internal normal lung control segment and a
lung segment receiving an active agent. In addition, all
stages of the disease, up to end-stage, can be examined
in a small specific lung segment, while the untreated re-
gions of the lung are healthy and can undertake normal
respiratory functions of a healthy animal. This is an
important consideration, as high mortality rates ap-
proaching 20-50 %, and significant initial weight loss
are common issues experienced in murine bleomycin
models which can confound injury responses in the
lungs [11, 12, 25].
It is important to note that, as with any animal model,
there are limitations to the sheep model that need to be
considered. Foremost, in attempting to replicate a com-
plex and poorly understood disease such as IPF, it is
nearly impossible to fully recapitulate the exact the na-
ture of the disease. Like other animal models of pulmon-
ary fibrosis, the sheep model induces fibrosis within a
relatively short time over a number of weeks, compared
to the natural history of IPF where human patients take
decades to develop the disease [1]. Animal models also
largely fail to create the progressive nature of fibrosis
seen in IPF where the pathology and lung function of
IPF patients deteriorate relatively rapidly after initial
diagnosis [4, 26]. Over time, the pulmonary fibrotic re-
sponses in animal models typically either plateau, or re-
solve, rather than progressively decline. Notwithstanding
this, studies in animal models are still an important tool
to help further our improved understanding of the dis-
ease and find suitable treatment and should be used syn-
ergistically to exploit the individual advantages each has
to offer. Therefore, the distinguishing features described
the sheep model should be used to complement other
experimental systems in contributing to the understand-
ing of pulmonary fibrosis.
The inclusion of physiological changes provides an
additional, more clinically relevant end-point in our
Fig. 8 Increased connective tissue levels seven weeks post-injury, as assessed with Masson’s trichrome staining and hydroxproline assay for
collagen. Representative images of Masson’s trichrome stained sections are shown for a saline-treated lung segment (a), and a bleomycin-treated
segment lung segment (b). The fibrotic fraction of each treatment (area of blue staining area/total field area) is shown in (c). Results show mean
± SEM, n=8. The panel (d) shows collagen content as determined using hydroxyproline assay. Significance was determined using paired
T-test ****p<0.0001
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model to assess fibrotic changes throughout a study.
Importantly, this is performed in a species with a re-
spiratory system that more closely resembles the struc-
ture and function of the human lung [27, 28]. Lung
function assessment in the current study shows that
there was a significant drop in segmental lung compli-
ance in the bleomycin treated segments, which persisted
for seven weeks following bleomycin injury. Importantly,
the lung function decline was significantly correlated
with pathology scores at 7 weeks post bleomycin. More-
over, sheep that showed progressive declines in lung
function over the study period were found to have the
most severe pathology, as indicated by the SMI scoring
data. This data is consistent with a number of early clin-
ical studies, which demonstrate a correlation between
structural and functional changes in IPF lungs [29, 30].
In these studies, lung function measurements of FVC,
gas exchange (dLCO) and compliance were correlated to
the extent of both fibrosis and cellularity in IPF patients
[29, 30]. The association between deteriorating lung
function and concomitant pathology has been ultimately
linked with the survivability of patients [26, 31]. The
overall significance of our findings was that sequential
lung function assessment in this large animal model
could serve as a reliable indication of the fibrotic
changes occurring in the lung.
To our knowledge, there are no other large animal
models for pulmonary fibrosis that examine histological
and physiological changes in the lung. In small animal
models, there are only a limited number of bleomycin
models that investigate changes to lung function beyond
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Fig. 9 Histopathology correlates to lung function changes. Graph
shows relationship between overall pathology score and lung
compliance in bleomycin-treated segments was assessed (n=9). The
measured compliance value (cm/H20) at 7 weeks was correlated to
the overall pathology score measured for the each
corresponding segment
Fig. 10 Myofibroblasts in bleomycin treated lung. Representative images of αSMA immunostaining seen in: saline-treated control lung segments
(a), showing localization predominantly around the interstitial space of alveolar duct (arrowheads). In bleomycin-treated segments (b) αSMA



































Fig. 11 Changes to TGF- β signalling in bleomycin-treated
segments. Levels of TGF- β protein were measured by ELISA using
BAL samples from bleomycin-treated segments. The samples were
taken at several key time points: baseline, or pre-bleomycin
treatment, 2 weeks post-bleomycin and 6 weeks post-bleomycin.
There was a significant increase in the amount of TGF- β at 2 weeks
post bleomycin in all segments. At 6 weeks post injury, there was
more variability in the level detected
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the acute stages of injury. In the majority of previously
published animal studies which utilize bleomycin as the
fibrotic agent and include lung function measurements,
bleomycin administration appears to have only had a
minor impact on pulmonary mechanics and is generally
only observable in the acute stage of injury, and not the
later fibrotic stages [8, 9]. Indeed, very few bleomycin
studies report physiological data as an end-point in pre-
clinical investigations, which is an obvious limitation for
these models. An exception is the recent study con-
ducted in mice using a relatively high single dose of
bleomycin which was able to detect measurable differ-
ences in lung function for up to 6 months after bleo-
mycin administration [12]. In that study, while there
were significant differences between control mice and
bleomycin-treated mice in lung function indices of diffu-
sion factor of carbon monoxide (DFco), total lung cap-
acity, and compliance at six months after bleomycin
administration, these parameters were all recovering to-
wards normal at this time-point [12].
Interestingly, our lung function data is consistent with
the TGF-β transgene model of pulmonary fibrosis in
rats, which has been able to demonstrate a similar re-
duction in lung compliance for up to 7 weeks after the
induction of fibrosis [32]. The degree of lung stiffness
was also negatively correlated to pathology scores in the
TGF-β rat model as we show for the sheep model [32].
This model utilizes adenovirus carrying active TGF-β1,
which causes a transient overexpression of the protein
to induce fibrosis [33]. This stimulates downstream pro-
fibrotic responses, rather than continual TGF-β1 pro-
duction, which result in the subsequent lung function
decline. This also appears to be the situation in the
current study, whereby transient TGF-β1 expression ap-
peared to be sufficient to result in self-propagation of
the fibrotic response that led to a loss of lung function.
Whilst both models showed similar physiological
changes, an asset of the sheep model we present here
was that physiological data could be obtained without
anesthesia or sedation and assessed throughout the en-
tire experimental period, including the period just before
cull. This allowed us to correlate compliance of individ-
ual lung segments with the fibrosis pathology in these
segments.
TGF-β is an important pro-fibrotic cytokine which
plays a central role in fibrosis [34]. The release of TGF-β
from injured epithelial cells and other sources results in
a fibrotic process with the accumulation of fibroblasts
and myofibroblasts in the injured area. These cell types
also express TGF-β to further stimulate this wound re-
sponse [34, 35]. In the current study, we found that in
TGF-β levels in BAL fluid were significantly increased in
all the bleomycin treated lobes 2 weeks after bleomycin
treatment. While at 6 weeks post treatment, the levels of
TGF-β were much more variable, with some sheep
showing increased expression, some unchanged, and
others decreased expression. These levels did not cor-
relate to other parameters, such as lung function, path-
ology or αSMA, expression (data not shown). As
mentioned above, transient TGF-β1 expression appears
to act as an important stimulus for the profibrotic
response and can lead to the activation fibrogenic
cytokines, including TNF-α, platelet-derived growth
factor, and basic fibroblast growth factor [33]. We have
previously shown by immunohistochemistry that TGF-
β labelling is particularly strong in alveolar epithelial
cells and hyperplastic Type II AEC cells, especially in
regions of more severe fibrosis [13]. These cell types, as
well as others in the lung, may contribute to the release
of TGB- β into lung luminal fluids. Interestingly, there
are differences in the literature regarding the duration
of TGF-β expression in the BALF in bleomycin murine
models. Early studies have shown peak expression at
14 days, returning to normal by 21 days after bleomycin
[36], whilst others are found increasing levels up to this
time point [37]. A more recent study suggests that peak
levels are detectable early, i.e. 3 days post bleomycin, in
the BAL and gradually recede [38]. This variability in
responses may be indicative that active TGF-β eventu-
ally becomes bound to components of matrix such as
the small proteoglycan biglycan [39], or fibronectin [40]
and is active in these regions, and therefore is no longer
detectable in the BAL fluid.
In this study, we found that overall injury and fibrotic
pathology, as assessed by a modified Ashcroft’s scoring
system, was similar in the bleomycin treated lobes at
7 weeks post injury to what was observed in our previ-
ous study at 2 weeks post bleomycin [13]. However, the
inflammation scores detected at 7 weeks post-injury
were significantly lower than that reported at 2 weeks
post-injury [13]. The persistence of fibrosis at the 7 week
time point was supported by data from both the hy-
droxyproline assay and Masson trichrome staining,
which indicate an increase in collagen deposition at this
time point compared with controls. The timing of the
fibrotic and inflammation responses in the sheep bleo-
mycin model is in accordance with the respective time-
frames typically exhibited in bleomycin rodent models,
where inflammation is observed up to 10–14 days post-
bleomycin and then subsides to give rise to the fibrotic
response, generally between day 21–28 after bleomycin
[6, 10].
The finding that fibrosis persists and the overall cellular-
ity of the lesions decreases over extended periods has been
reported for bleomycin models in rodents that use both
multi-hit [7, 11] and single dose methods [10, 38], but not
by others using rodent models where the fibrosis resolved
over 6 weeks post-injury [8, 9]. Whilst our findings are
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comparable with the studies showing persistent fibrosis [7,
10, 11, 38], one defining point of difference between the
rodent and sheep models is the pattern of fibrosis ob-
served in the sheep model. In general, intratracheal ad-
ministration of bleomycin in rodent models typically
produces a peribronchiolar pattern of fibrosis [8, 41],
whilst IV administration of bleomycin to mice induces
perivascular fibrosis [10, 41], of which both patterns are
more commonly observed other lung diseases, such as
asthma and COPD [23, 42]. In contrast, the patchy fibrosis
observed in our study is found predominantly in the lung
parenchyma, which is consistent with the pattern of fibro-
sis reported for IPF patients [1].
The sustained fibrotic response may reflect a prevail-
ing profibrogenic environment within the bleomycin
treated lung segments of sheep, as suggested by the in-
creased positive αSMA immuno-staining found within
the injured region of the segments. αSMA is a recog-
nized indicator for the presence of myofibroblasts [43], a
cell type which is known to be extensively localized in fi-
brotic lesions of IPF lungs [44]. It has been shown that
the persistent presence of myofibroblasts appears to be a
primary driver of the progression of fibrosis in IPF [45].
In bleomycin-induced fibrosis, the increased presence of
the myofibroblast was found to occur in parallel to in-
creased fibrotic injury [38]. The myofibroblast has been
associated with the expression of several matrix proteins
which contribute to matrix deposition [46].
Radiological examination of the lung is the primary
method used to determine the presence of UIP and a
diagnosis of IPF and is also used to help monitor the
progression of fibrosis and stage of severity of disease
[1]. Software programs, such as the one used in the
current study allow for 3D reconstruction of the scanned
area, which can then subsequently be measured and the
specific density range can be quantified. In the current
study, we chose to assess the radiological changes in the
lungs of the sheep that had showed the worst lung func-
tion throughout the study to confirm that injury in the
lung occurred in the segment treated with bleomycin.
Additionally, this also enabled us to determine if this
tool could be incorporated into our assessment of fibro-
sis, as has been successfully done in murine models [10,
32] The scan was performed ex-vivo for practical rea-
sons, as it eliminated the need to anesthetize and trans-
port the sheep for the procedure, similar to that
previously published in a pre-clinical mice model [10].
In CT images, fibrotic lung tissue appeared denser com-
pared to normal lungs, which was very clearly visualised
on the images obtained from our sheep lung, showing a
clear demarcation of the region locally treated with bleo-
mycin compared to the remainder of the lung. This re-
sult suggested that ex-vivo CT scans could serve as a
non-invasive tool for the assessment of fibrotic changes
and intervention strategies in future studies, similar to
that done by others [10, 32].
Conclusion
In conclusion, the results from the current study demon-
strated that a relatively sustained fibrotic response could be
induced into isolated lung segments that also lead to a per-
sistent, measurable change in lung compliance. Import-
antly, the changes in segmental compliance correlate
strongly to pathology; therefore this parameter can serve as
a reliable indicator of pathological changes in the lung. The
assessment of lung function in this model is therefore likely
to be a useful predictor of the efficacy of different interven-
tion strategies against pulmonary fibrosis in future preclin-
ical studies. The inclusion of more clinically relevant end-
points into pre-clinical trials may aid in more accurate
identification of potential drug candidates to translate into
the clinic.
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